160 related articles for article (PubMed ID: 16926548)
1. Evolution of hepatitis C virus quasispecies during ribavirin and interferon-alpha-2b combination therapy and interferon-alpha-2b monotherapy.
Arataki K; Kumada H; Toyota K; Ohishi W; Takahashi S; Tazuma S; Chayama K
Intervirology; 2006; 49(6):352-61. PubMed ID: 16926548
[TBL] [Abstract][Full Text] [Related]
2. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.
Gerotto M; Sullivan DG; Polyak SJ; Chemello L; Cavalletto L; Pontisso P; Alberti A; Gretch DR
J Virol; 1999 Sep; 73(9):7241-7. PubMed ID: 10438811
[TBL] [Abstract][Full Text] [Related]
3. Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.
Veillon P; Payan C; Le Guillou-Guillemette H; Gaudy C; Lunel F
World J Gastroenterol; 2007 Feb; 13(8):1195-203. PubMed ID: 17451199
[TBL] [Abstract][Full Text] [Related]
4. Effect of ribavirin on the frequency of RNase L cleavage sites within the hepatitis C viral genome.
Mihm U; Hofmann WP; Welsch C; Polta A; Lengauer T; Zeuzem S; Sarrazin C; Herrmann E
J Viral Hepat; 2010 Mar; 17(3):217-21. PubMed ID: 19758279
[TBL] [Abstract][Full Text] [Related]
5. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations.
Pawlotsky JM; Germanidis G; Neumann AU; Pellerin M; Frainais PO; Dhumeaux D
J Virol; 1998 Apr; 72(4):2795-805. PubMed ID: 9525599
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C.
Puig-Basagoiti F; Forns X; Furčić I; Ampurdanés S; Giménez-Barcons M; Franco S; Sánchez-Tapias JM; Saiz JC
J Gen Virol; 2005 Apr; 86(Pt 4):1067-1075. PubMed ID: 15784900
[TBL] [Abstract][Full Text] [Related]
7. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin.
Hung CH; Lee CM; Lu SN; Lee JF; Wang JH; Tung HD; Chen TM; Hu TH; Chen WJ; Changchien CS
J Viral Hepat; 2003 Mar; 10(2):87-94. PubMed ID: 12614464
[TBL] [Abstract][Full Text] [Related]
8. Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.
Yano Y; Seo Y; Miki A; Saito M; Kato H; Hamano K; Oya M; Ouchi S; Fujisawa T; Yamada H; Yamashita Y; Tani S; Hirohata S; Yoon S; Kitajima N; Kitagaki K; Kawara A; Nakashima T; Yu H; Maeda T; Azuma T; El-Shamy A; Hotta H; Hayashi Y;
Int J Mol Med; 2012 Nov; 30(5):1048-52. PubMed ID: 22899224
[TBL] [Abstract][Full Text] [Related]
9. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.
Vuillermoz I; Khattab E; Sablon E; Ottevaere I; Durantel D; Vieux C; Trepo C; Zoulim F
J Med Virol; 2004 Sep; 74(1):41-53. PubMed ID: 15258967
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the NS5A gene are associated with response to interferon+ribavirin combination therapy in patients with chronic hepatitis C virus 3a infection.
Ullah S; Rehman HU; Idrees M
Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1146-51. PubMed ID: 23611896
[TBL] [Abstract][Full Text] [Related]
11. Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy.
Hofmann WP; Polta A; Herrmann E; Mihm U; Kronenberger B; Sonntag T; Lohmann V; Schönberger B; Zeuzem S; Sarrazin C
Gastroenterology; 2007 Mar; 132(3):921-30. PubMed ID: 17383421
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
Bolcic F; Laufer N; Torres C; Cassino L; Reynoso R; Quarleri J
Antiviral Res; 2012 Aug; 95(2):72-81. PubMed ID: 22683884
[TBL] [Abstract][Full Text] [Related]
13. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.
Chambers TJ; Fan X; Droll DA; Hembrador E; Slater T; Nickells MW; Dustin LB; Dibisceglie AM
J Virol; 2005 Mar; 79(5):3071-83. PubMed ID: 15709027
[TBL] [Abstract][Full Text] [Related]
14. Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy.
Querenghi F; Yu Q; Billaud G; Maertens G; Trépo C; Zoulim F
J Viral Hepat; 2001 Mar; 8(2):120-31. PubMed ID: 11264732
[TBL] [Abstract][Full Text] [Related]
15. Effects of ribavirin monotherapy on the viral population in patients with chronic hepatitis C genotype 1: direct sequencing and pyrosequencing of the HCV regions.
Quiles-Pérez R; Muñoz-de-Rueda P; Maldonado AM; Martín-Álvarez A; Quer J; Salmerón J
J Med Virol; 2014 Nov; 86(11):1886-97. PubMed ID: 25091333
[TBL] [Abstract][Full Text] [Related]
16. RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
Le Pogam S; Seshaadri A; Ewing A; Kang H; Kosaka A; Yan JM; Berrey M; Symonds B; De La Rosa A; Cammack N; Nájera I
J Infect Dis; 2010 Nov; 202(10):1510-9. PubMed ID: 20942646
[TBL] [Abstract][Full Text] [Related]
17. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
[TBL] [Abstract][Full Text] [Related]
18. Variations in the viral NS5B region in Japanese patients with chronic hepatitis C virus genotype 1b infection. No specific amino acid substitution was identified as determinants of treatment response to interferon/ribavirin combination therapy.
Sugihara K; Orito E; Tanaka Y; Kato T; Lau JY; Ohno T; Hayashi K; Ogino M; Hirashima N; Sakakibara K; Mizuno Y; Kato H; Suzuki S; Ueda R; Mizokami M
Intervirology; 2006; 49(6):319-26. PubMed ID: 16926544
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of serum hepatitis C virus load and quasispecies complexity during antiviral therapy in patients with chronic hepatitis C.
Grahovac B; Bingulac-Popovic J; Vucelic B; Hrstic I; Ostojic R; Drazic V; Balija M; Grgicevic D
J Clin Virol; 2001 Jan; 20(1-2):85-9. PubMed ID: 11163588
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin.
Yang SS; Lai MY; Chen DS; Chen GH; Kao JH
Liver Int; 2003 Dec; 23(6):426-33. PubMed ID: 14986817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
